Drugmakers Fight To Undo Loestrin Antitrust Class Cert.
Warner Chilcott and Watson Pharmaceuticals want the First Circuit to take up their appeal of a class certification ruling in a suit alleging they delayed generic alternatives to the birth control...To view the full article, register now.
Already a subscriber? Click here to view full article